Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LXH254 · 1 trial · 1 indication
Confirmed ORR using RECIST v1.1, per local assessment
| Arm | Type | Description |
|---|---|---|
| LXH254 + LTT462 | EXPERIMENTAL | - |
| LXH254 + trametinib | EXPERIMENTAL | - |
| LXH254 + ribociclib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LXH254 | DRUG | LXH254 will be supplied as tablet for oral use. |
| LTT462 | DRUG | LTT462 will be supplied as hard gelatin capsule for oral use. |
| Trametinib | DRUG | Trametinib will be supplied as film-coated tablet for oral use |
| Ribociclib | DRUG | Ribociclib will be supplied in tablets and hard gelatin capsules. |
Inclusion Criteria: Male or female must be ≥ 12 years For adolescents only (12-17 years): body weight \> 40kg Histologically confirmed unresectable or metastatic cutaneous melanoma Previously treated for unresectable or metastatic melanoma: * Participants with NRAS mutation: * Participants must h...
Top 20 of 52 competitors